drugset

drugset / Trial / NCT00095810

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

NCT00095810 ↗

Phase 4 Completed 50 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Timeline

Start: 2003-07
Primary completion: 2004-09
Completion: 2004-09

Publications

Background Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec;21(12):2078-81. doi: 10.1002/mds.21091.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aripiprazole	Other / unclassified	1 mg	Oral
Subject	Aripiprazole	Other / unclassified	10 mg	Oral

Indications